clinical trial · NCT07086313
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd.·phase3·recruiting·n = 315
Attention-Deficit Hyperactivity Disorder(ADHD)EB-1020 (Centanafadine) low doseEB-1020 (Centanafadine) high dosePlacebo
brief summary
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
started
Sep 3, 2025
primary completion
Aug 1, 2027
completion
Aug 1, 2027
last updated
Dec 23, 2025
official title
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Japan-China Joint Trial to Evaluate the Efficacy and Safety of Two Dose Levels of EB-1020 QD XR Capsules Administered Orally Once Daily in Children and Adolescents With Attention-deficit/Hyperactivity Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol